Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers 
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3121
Abstract: To address the need for targeted therapy in the treatment of HER3-positive solid tumors, the human HER3 mAb, seribantumab, was evaluated in the context of an antibody-drug conjugate (ADC). As a proof-of-concept, seribantumab was conjugated… read more here.
Keywords: her3; isotype; patri dxd; her3 adc1 ... See more keywords
Abstract LB004: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-lb004
Abstract: The overexpression of HER3 in solid tumors is associated with poor prognosis. Therapies developed to target HER3-mediated signaling are often associated with resistance over time, highlighting the need to develop differentiated therapeutic strategies. To address… read more here.
Keywords: cancer; mmae; solid tumors; patri dxd ... See more keywords